Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin

V.M. Quintana1, N.I. Torres†1, M.B. Wachsman1, P.J. Sinko2, V. Castilla1* and M. Chikindas3*

1 Laboratorio de Virología, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Ciudad Autónoma de Buenos Aires, Argentina
2 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA
3 School of Environmental and Biological Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA

Keywords
antimicrobial peptide, antiviral activity, bacteriocin, herpes simplex virus, microbicide, subtilosin.

Correspondence
E-mail: viviana@qb.fcen.uba.ar

†Present address: Laboratorio de Fisiopatología de la Inmunidad Innata, Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado, 2490, Ciudad Autónoma de Buenos Aires, C1428ADN, Argentina

*These authors contributed equally to this work.

2014/0776: received 14 April 2014, revised 30 June 2014 and accepted 30 July 2014
doi:10.1111/jam.12618

Abstract

Aims: In this study, we evaluated the antiviral activity of subtilosin, a cyclical peptide isolated from Bacillus amyloliquefaciens, against herpes simplex virus type 2 (HSV-2) in cell cultures and we investigated subtilosin mode of action.

Methods and Results: We determined, using a virus yield inhibition assay, that noncytotoxic concentrations of subtilosin inhibit HSV-2 replication in Vero cell cultures. Subtilosin strongly inhibited extracellular and total virus production even when it was added at 8 h postinfection indicating that not only virus release but also viral particle formation is impeded by the antiviral peptide. Although viral glycoprotein gD level of expression is not affected by the bacteriocin, an altered pattern of gD intracellular localization was detected by immunofluorescence assay in subtilosin-treated culture. On the other hand, at high concentrations, subtilosin displays virucidal action.

Conclusions: Subtilosin displays antiviral and virucidal actions against HSV-2. The target of subtilosin inhibitory effect would be late stages of the viral replicative cycle such as viral glycoprotein intracellular transport.

Significance and Impact of the Study: Given its antimicrobial activity and its safety for human tissues, subtilosin could represent a valuable alternative to be considered in the development of new microbicide formulations.

Introduction

Subtilosin, a ribosomally synthesized 3-4-kDa cyclical peptide (Marx et al. 2001) produced by both Bacillus subtilis (Bahasaki et al. 1985) and Bacillus amyloliquefaciens (Sutyak et al. 2008a), is a bacteriocin that has the potential for applications in contraception and reproductive health due to its unique properties, such as natural origin, biodegradability, antimicrobial activity, lack of immunogenicity, overall safety, ease of production and formulation (Sutyak et al. 2008b; van Kuijk et al. 2012; Noll et al. 2012; Turovskiy et al. 2012). Previous studies have demonstrated that subtilosin reduces sperm motility in vitro in a dose-dependent fashion (Sutyak et al. 2008b). This compound also displays antimicrobial activity against the foodborne pathogen Listeria monocytogenes Scott A (van Kuijk et al. 2012) and against bacterial vaginosis-associated pathogen Gardnerella vaginalis, including their antibiotic-resistant forms (Noll et al. 2012; Turovskiy et al. 2012).

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are human viral pathogens that cause serious clinical diseases comprising genital ulcerations, corneal blindness, cold sores and encephalitis. Patients with immune deficiencies have an increased risk of developing severe HSV infection, and vertical transmission of HSV-1 or HSV-2 to the newborn can cause fatal neonatal encephalitis.
transmitted disease (STD) (Fife et al. 2008; Chentoufi and Benmohamed 2012). On the other hand, epidemiologic studies suggest there is synergy between HSV-2 and human immunodeficiency virus type 1 (HIV-1); HSV-2 reactivation increases HIV-1 concentrations in plasma and genital secretions, whereas co-infection with HIV-1 would increase HSV-2 transmission risk (Freeman et al. 2006; Thurman and Doncel 2012; Des Jarlais et al. 2014).

The first antiviral chemotherapy for the management of herpetic infections was treatment with acyclovir (ACV), an analogue of the natural nucleoside guanosine. The triphosphate form of this analogue selectively inhibits the viral DNA polymerase activity, thus inhibiting viral replication. Drug-resistant HSV isolates are frequently found in vitro and in immunocompromised patients (Choong et al. 2010; van Velzen et al. 2012). Foscarnet (FOS), a pyrophosphate analogue, is often administered in ACV-resistant HSV infections. Nevertheless, its use is reserved to patients where other drugs fail due to its high toxicity and low bioavailability (Chilukuri and Rosen 2003). Furthermore, it has been shown that antiviral treatment of herpetic infection fails to completely prevent HSV and HIV transmission (Johnston et al. 2012). Considering that even in treated patients the infection persists during the lifetime of the host (Efstatthiou and Preston 2005), the lack of an effective vaccine (Belshe et al. 2012) and the reported emergence of HSV-resistant mutants, there is a need to develop new antitherpetic compounds with different mechanisms of action.

Interestingly, in a previous study, we reported that subtilosin affects HSV-1 infectivity by two mechanisms: the bacteriocin acts as a virucidal agent and as an inhibitor of HSV-1 multiplication in cell cultures (Torres et al. 2013). In addition to its antimicrobial properties, subtilosin does not harm vaginal tissues and does not interfere with the healthy vaginal lactobacilli (Sutyak et al. 2008b; Noll et al. 2012; Torres et al. 2013). Therefore, subtilosin is a promising nontoxic spermicide and has concomitant antimicrobial properties that may promote healthy vaginal microflora. In this study, we examined the susceptibility of HSV-2 to subtilosin treatment in cell cultures and explored subtilosin mode of action.

Materials and methods

Compounds

Subtilosin was purified from cultures of *B. amylo liquefaciens* KATMIRA1933, as previously described by Sutyak et al. (Sutyak et al. 2008a). Essentially, the overnight culture’s supernatant was filter-sterilized (0.45 μm filter, Millipore, Billerica, MA), concentrated using 30% ammonium sulphate, resuspended in water and fractionated using Sep-Pak® Light C18 cartridges (Waters, Milford, MA). The sample was subjected to the step-gradient Tricine-SDS-PAGE (Bio-Rad, Hercules, CA) and silver stain visualized as a single band. In the overlay test with the bacteriocin-sensitive reference strain of *Micrococcus luteus*, this PAGE protein band produced a single zone of inhibition (data not shown). Subtilosin was diluted with maintenance medium (MM) consisting of minimum essential medium (MEM) (Gibco, Carlsbad, CA) with 2% inactivated foetal bovine serum and 50 μg ml⁻¹ of gentamycin.

Cells and viruses

African green monkey kidney (Vero) cells were grown as monolayers in MEM supplemented with 5% inactivated foetal bovine serum and 50 μg ml⁻¹ of gentamycin. HSV-2 strain G was obtained from the American Type Culture Collection (Rockville, MD). Virus stock was prepared in Vero cells.

Cell cytotoxicity assay

To assess the effect of subtilosin on cell viability, confluent monolayers of Vero cells grown in 96-well culture plates were incubated with different concentrations of subtilosin for 48 h at 37°C. Then, cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO) procedure (Denizot and Lang 1986). Cytotoxicity was expressed as the 50% cytotoxic concentration (CC₅₀) which is the concentration of subtilosin that reduced cell viability by 50% with respect to the cellular control.

Virus yield inhibition assay

Antiviral activity was evaluated by a virus yield inhibition assay. To this end, Vero cells, grown in 24-well culture plates, were infected with HSV-2 at a multiplicity of infection (m.o.i.) of 1 PFU per cell. After 1 h of adsorption at 37°C, virus inoculum was discarded and cells were covered with MM (control) or MM containing serial dilutions of subtilosin. After 24 h of incubation at 37°C, the supernatants were harvested and extracellular virus yields were determined by a plaque formation assay. The antiviral activity was expressed as the 50% effective concentration (EC₅₀), that is the compound concentration of subtilosin required to reduce virus yield by 50% compared with the untreated infected culture. The selectivity...
index (SI) was calculated as the ratio between CC50 and EC50 values.

**Virucidal assay**

To assay virucidal activity of the bacteriocin, HSV-2 was incubated with subtilosin at concentrations ranging from 25 to 200 µg ml⁻¹ or MM for 90 min at 37°C. After the incubation period, aliquots were conveniently diluted in MM and remaining infectivity was determined by plaque assay on Vero cells.

**Time of addition experiment**

Subtilosin (50 µg ml⁻¹) was added to Vero cells, either during 6 h before the infection with HSV-2 (m.o.i. = 1) or at 1, 3, 5 or 8 h postinfection (p.i.). Cultures were incubated up to 24 h p.i., and at that time, supernatants were harvested to assess extracellular virus titre. Another set of identically infected-treated cultures were subjected to two freeze–thaw cycles, followed by low-speed centrifugation to quantify total (extracellular and intracellular) viral infectivity. Virus titres were determined by plaque formation assay.

**Indirect immunofluorescence (IF) assay**

Vero cells grown on glass coverslips were infected with HSV-2 at an m.o.i. of 1 PFU per cell. After 1 h adsorption at 37°C, cultures were incubated in MM containing or not subtilosin 25, 50 or 100 µg ml⁻¹ and incubated at 37°C for 24 h. After the removal of culture supernatants, cells were washed with cold PBS, fixed with cold methanol (20 min at −20°C) and then incubated with a mouse monoclonal antibody reactive against gD viral glycoprotein (Santa Cruz Biotechnology Inc., Santa Cruz, CA) for 45 min at 37°C. The indirect staining was carried out using goat anti-mouse immunoglobulins conjugated to FITC (Sigma-Aldrich). Fluorescent cells were photographed with a Zeiss microscope with epifluorescence optics.

**Western blot assay**

Vero cells were infected with HSV-2 (m.o.i. = 1), and after virus adsorption, cells were incubated in MM containing or not subtilosin 25, 50 or 100 µg ml⁻¹ and incubated at 37°C for 24 h. Then, cells were lysed and samples were subjected to SDS-PAGE and transferred to PVDF membrane (Perkin Elmer Life Sciences, Inc., Waltham, MA) in a dry system (LKB Multiphor II, Pharmacia, Uppsala, Sweden). Viral glycoprotein gD was revealed using mouse anti-gD (Santa Cruz Biotechnology Inc.), and GAPDH, used as loading control, was detected with mouse anti-GAPDH (Abcam, Cambridge, UK). Peroxidase-conjugated anti-mouse immunoglobulin G (Promega, Madison, WI) was used as secondary antibody. The intensities of protein bands, visualized by chemiluminescence detection, were quantified using Image J software, and the relative intensity gD/GAPDH was calculated for each sample.

**Statistical analysis**

The 95% confidence intervals (CI) of virus titres were calculated according to Poisson distribution.

**Results**

**Antiviral activity of subtilosin against HSV-2**

First, we evaluated the effect of treatment with different concentrations of subtilosin on Vero cell viability using the MTT method. The CC50 value of subtilosin in Vero cells was 316.8 µg ml⁻¹. Then, we performed a virus yield inhibition assay using noncytotoxic concentrations of subtilosin. A dose-dependent inhibition of virus yield was observed in subtilosin-treated cultures (Fig. 1). At 25 µg ml⁻¹, subtilosin inhibited virus replication by almost 90%, whereas at 200 µg ml⁻¹, a reduction over 99.9% in virus titre was achieved (Fig. 1). The EC50 and SI values of subtilosin against HSV-2 were 18.2 µg ml⁻¹ and 17-4, respectively.

![Figure 1](image-url)
Virucidal action of subtilosin

Taking into account previous studies that showed that at high concentrations subtilosin display virucidal activity against HSV-1 (Torres et al. 2013), we evaluated the effect of subtilosin on HSV-2 particles by incubating aliquots of viral stock with different concentrations of subtilosin during 90 min at 37°C. As can be seen in Fig. 2, at the highest concentration tested (200 µg ml⁻¹), subtilosin exhibited a direct inactivating effect on viral particles since after 90 min of treatment, a 99.99% reduction of HSV-2 infectivity was observed. However, at 100, 50 or 25 µg ml⁻¹, concentrations that displayed antiviral activity (Fig. 1), subtilosin showed no relevant virucidal effect (Fig. 2).

Characterization of subtilosin antiviral activity

To characterize subtilosin inhibitory action against HSV-2, a time of addition experiment was performed. Vero cells were treated with subtilosin (50 µg ml⁻¹) for 6 h prior to infection or at different times after infection. In all cases, extracellular and total virus production were determined at 24 h p.i. Subtilosin treatment of cells before infection did not affect virus production indicating that the peptide does not induce an antiviral state on the cell culture. On the contrary, the presence of subtilosin from 1, 3, 5 or 8 h p.i reduced total virus titre by approx. 6 log units and the amount of infectious virus released to the extracellular medium was also strongly inhibited (Fig. 3). The same level of reduction in virus production was observed when subtilosin was added at 1 or 8 h p.i., thus a possible explanation for these results is that a late stage on the viral replicative cycle would be blocked by subtilosin.

Discussion

The lifelong HSV-2 infection is the principal cause of genital ulcer disease, and it is also a contributing factor in the increase of acquisition and transmissibility of HIV infection (Des Jarlais et al. 2014; Gottlieb et al. 2014). In
the last years, great efforts have been made to develop new antiviral molecules effective against HSV including those viral strains that are resistant to nucleoside analogues (Wald et al. 2014). In a previous work, we have described the ability of subtilosin to inhibit the multiplication of ACV-susceptible and ACV-resistant strains of HSV-1 (Torres et al. 2013). Here, we demonstrate that subtilosin is also an effective inhibitor of HSV-2 multiplication, and we further characterize the antiviral mode of action of this bacterial peptide.

Although antiviral activity of several antimicrobial peptides isolated from different bacteria genera has been previously reported (Wachsman et al. 1999, 2003; Serkedjieva et al. 2000; Todorov et al. 2005, 2010; Saeed et al. 2007; Féir et al. 2013), no virucidal effect was described for these bacteriocins and up to now much remains unknown about their inhibitory mechanism of action. CRL5, peptide isolated from Enterococcus faecium, exhibits an inhibitory effect on HSV-1 late viral protein synthesis (Wachsman et al. 2003), whereas the lantibiotic peptide Labyrinthopeptin A1 produced by Actinomadura namibiensis blocks an early after-adsorption step of HIV multiplication (Féir et al. 2013).

Our results show that pretreatment with subtilosin did not protect cells from infection. This indicates that subtilosin should be present during viral multiplication to exert its inhibitory action and also suggests that the bacteriocin does not cause an irreversible effect on host cell functions. However, the addition of subtilosin after HSV-2 infection strongly inhibited both extracellular and total virus production, indicating that not only virus release but also viral particle formation is blocked by bacteriocin treatment. The same level of inhibition was achieved when subtilosin was added between 1 and 8 h p.i. indicating that early events of HSV-2 multiplication cycle are not affected by the bacteriocin.

Furthermore, the analysis of the expression of viral glycoprotein gD showed that although gD production is not affected by the bacteriocin, an altered pattern of gD intracellular localization in subtilosin-treated cultures was observed suggesting that subtilosin would affect gD intracellular transport. Future studies will be necessary to establish the precise cellular compartment in which gD

---

**Figure 4** Intracellular localization of gD glycoprotein in subtilosin-treated cells. Cytoplasmic immunofluorescence staining of HSV-2-infected Vero cells in the absence (a) or in the presence of 100 µg ml⁻¹ (b), 50 µg ml⁻¹ (c) or 25 µg ml⁻¹ (d) subtilosin. Magnification 400×.

**Figure 5** gD production in subtilosin-treated cells. HSV-2-infected Vero cells were treated with different concentrations of subtilosin, and at 24 h p.i., the expression of viral protein gD and cellular protein GAPDH, used as loading control, was assessed by Western blot. The relative intensity of gD band with respect to GAPDH band for each sample of one representative experiment is shown.
accumulates after subtilosin treatment. Taking together, these results indicate that the target of subtilosin antiviral action are late stages of virus replication, thus hindering viral particle formation.

Besides its inhibitory effect and in coincidence with the results obtained with HSV-1 (Torres et al. 2013), at high concentrations, subtilosin also exhibits virucidal action against HSV-2. Altogether, our results show that subtilosin mode of antiviral action seems to be clearly different to those previously described for other bacteriocins (Serkedjieva et al. 2000; Wachsman et al. 2003; Férib et al. 2013).

Control of transmission of STDs includes the use of topically applied microbicides that inactivate the relevant pathogens; thus, virucidal agents provide a good source of developing new microbicidal formulations. Bacteriocins are attractive natural alternatives to classic antibiotics and virucidal agents, which could be used for the treatment of bacterial and viral infections. The ability of subtilosin to inactivate both HSV-1 and HSV-2 particles, together with its spermicidal activity and safety of subtilosin-based nanofibres for use on human skin tissues (Sutyak et al. 2008b; Torres et al. 2013), makes this peptide a promissory candidate to be included in new studies concerning the design of nanofibre systems containing a combination of antimicrobial and anti-inflammatory drugs to be proved in animal models.

Acknowledgements

This work was funded by grant from Universidad de Buenos Aires (20020110100076); P.J.S. and M.L.C. were supported by the Bill and Melinda Gates Foundation Grand Challenges Exploration (Round 5, Phase I Grant OPP1025200) and by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (1R01AI084137).

Conflict of interest

We have no conflicts of interest to disclose.

References


